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Abstract
Background: Our goal is to use gene therapy to alleviate pain by targeting glial cells. In an animal
model of facial pain we tested the effect of transfecting the glutamic acid decarboxylase (GAD) gene
into satellite glial cells (SGCs) of the trigeminal ganglion by using a serotype 5 adenovector with
high tropisms for glial cells. We postulated that GABA produced from the expression of GAD
would reduce pain behavior by acting on GABA receptors on neurons within the ganglion.
Results: Injection of adenoviral vectors (AdGAD65) directly into the trigeminal ganglion leads to
sustained expression of the GAD65 isoform over the 4 weeks observation period.
Immunohistochemical analysis showed that adenovirus-mediated GAD65 expression and GABA
synthesis were mainly in SGCs. GABAA and GABAB receptors were both seen in sensory neurons,
yet only GABAA receptors decorated the neuronal surface. GABA receptors were not found on
SGCs. Six days after injection of AdGAD65 into the trigeminal ganglion, there was a statistically
significant decrease of pain behavior in the orofacial formalin test, a model of inflammatory pain.
Rats injected with control virus (AdGFP or AdLacZ) had no reduction in their pain behavior.
AdGAD65-dependent analgesia was blocked by bicuculline, a selective GABAA receptor antagonist,
but not by CGP46381, a selective GABAB receptor antagonist.
Conclusion: Transfection of glial cells in the trigeminal ganglion with the GAD gene blocks pain
behavior by acting on GABAA receptors on neuronal perikarya.
Background
Pain sensation most commonly results from the activa-
tion of peripheral branches of primary sensory neurons,
the perikarya of which are located in either dorsal root
ganglia (DRG) for body sensation or the trigeminal gan-
glia for sensation from the face. The central branches of
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the spinal cord and those of the trigeminal ganglion in the
brainstem trigeminal nucleus. Injury to tissue or periph-
eral nerve induces central nervous system sensitization,
facilitating pain processing responsible for allodynia and
hyperalgesia [1,2]. A number of studies have shown that
reducing the activity of primary afferents is often sufficient
to alleviate peripherally generated pain conditions.
One approach to reducing neuronal activity is through the
use of the inhibitory transmitter gamma-aminobutyric
acid (GABA). Although there is an abundant literature
showing the antinociceptive efficacy of GABA-acting
drugs, most reports have been related to GABA manipula-
tion in the central nervous system (CNS). Recently, how-
ever, Naik and colleagues [3] have shown that the
application of GABA agonists to DRG led to a reduction of
pain behavior in a model of sciatic nerve crush injury. The
effect is theoretically not unexpected as there is evidence
that both GABAA and GABAB receptors are expressed by
primary sensory neurons in the trigeminal ganglia and
DRG [4,5]. While it is likely that these receptors are prin-
cipally exported to central terminals, some evidence sug-
gest that they are also functional at the cell body within
the ganglia [3,4]. On the basis that GABA receptors are
present on neuronal perikarya in the ganglion, increasing
GABA in the ganglia should reduce neuronal excitability
and in pain conditions and potentially result in antinoci-
ception.
A recent strategy to induce GABA production has been to
use viral vectors to introduce the synthetic enzyme for
GABA, glutamic acid decarboxylase (GAD), into primary
sensory neurons by inoculating the virus into subcutane-
ous tissue, to obtain retrograde transport to the sensory
neuron bodies. The general advantage of this method is
that the effects of gene based therapies are long lived with-
out repeated dosing and are targeted to the affected area
thus avoiding systemic effects. Peripheral inoculation of
herpes simplex virus (HSV), leads to antinociception in a
model of central neuropathic pain from spinal cord injury
[6] as well as in a model of peripheral neuropathic pain
after spinal nerve ligation [7]. More recently, the transfer
of GAD67 to DRG neurons by peripheral inoculation of a
novel human foamy virus (HFV) was shown to reduce
nociceptive responses associated with spinal cord
hemisection [6,8]. In these experiments increased expres-
sion of GAD67 mRNA was demonstrated in DRG and an
increase in extracellular GABA was found in the spinal
cord [8], suggesting that most of the analgesic effect
resulted from GABA expression in sensory neurons fol-
lowed by transport and release from terminals in the CNS.
In the present study, we wished to target glial cells to
induce the production of GABA in the trigeminal ganglion
itself. Within sensory ganglia the primary sensory neurons
are tightly enveloped by a specialized cell, the satellite
glial cell (SGC). In theory, if SGCs were induced to release
GABA, then the activity of sensory neurons within the
ganglion would be suppressed through activation of
locally expressed GABA receptors. There are currently
many attempts using cell-specific promoters to produce
cell specific viral agents [9] but it is also known that some
viruses have a 'natural' preference for a specific cell type
[10-13]. We found an adenovector that preferentially
infected SGCs and used this virus to transfer GAD65, one
of the two GAD isoforms, into SGCs in order to produce
GABA within the trigeminal ganglion.
We injected the adenovector directly into the trigeminal
ganglion in order to infect SGCs then we confirmed the
expression and location of GAD65 and GABA. To test the
effects of the gene transfer on nociception, we used the
orofacial formalin test, a standard model of inflammatory
pain. To determine if the behavioral effect of the transgene
occurred because of its expression within the trigeminal
ganglion, we tested the effects of GABAA and GABAB
receptor antagonists injected directly into the ganglion.
Results
Adenovirus-mediated expression of GAD65 occurs mainly 
in satellite glial cells (SGCs) in the trigeminal ganglion
The trigeminal ganglion is characterized by elongated
clusters of sensory neurons lying between bundles of mye-
linated axons (Figure 1A). The cell bodies of primary sen-
sory neurons are surrounded by satellite glial cells (SGCs).
In Nissl preparations the nuclei of SGCs are visible but the
cytoplasm surrounding the neurons is attenuated and not
readily visible (Figure 1B). To identify the SGCs we used
glial specific markers involved in glutamate metabolism,
glutamine synthetase (Figure 1C) and glutamate trans-
porter GLAST (Figure 1E2). Six days after injection of
AdGAD65 into the trigeminal ganglion a region approxi-
mately 750 μm × 2500 μm showed GAD65 structures that
included 50–70% of the SGCs (Figures 1D; E1–E3). Only
an occasional GAD65 immunopositive neuron was seen
(Figure 1F) but other, elongated, fiber-like immunoposi-
tive elements were present throughout the ganglion. To
see whether the immunolabeled elements were axons we
double stained using the NF160 neurofilament antibody
(Figure 1G1–G3) and found none of the elongated struc-
tures were double labelled. The lack of axonal staining
confirms the observation that only an occasional neuron
was infected. Many of the elongated profiles appeared cel-
lular (Figure 1H) and many of these double labelled with
the neurotrophin receptor, P75 (Figure 1I), or the
Schwann cell marker, Sch2E (Figure 1J), indicating that
they were non-myelinating or myelinating Schwann cells.
In some regions of the injected area the number of
labelled SGCs and Schwann cells were approximatelyPage 2 of 11
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Adenovirus-mediated expression of GAD65 in the trigeminal ganglionFigure 1
Adenovirus-mediated expression of GAD65 in the trigeminal ganglion. (A) Nissl stain showing the anatomical organ-
ization of the rat trigeminal ganglion with elongated clusters of sensory neurons (arrows) lying between bundles of myelinated 
axons. (B) At high magnification only the nuclei of SGCs (arrows) that surround the unipolar sensory neuron (N) are visible. 
(C) The attenuated cytoplasm of the SGCs is visible using the glial-specific marker, glutamine synthetase (arrows, green). 
Arrowheads point to SGC nuclei. (D) A low magnification image of the whole ganglion (outlined by arrowheads) showing the 
extent of GAD65 immunopositive elements (green) following injection of adGAD65. Images E1-F3 are taken 6 days after 
injection of AdGAD65 into the trigeminal ganglion. (E1-E3) GAD 65 expression (E1, green) is found in SGCs identified by 
GLAST immunostaining (E2, red) and in other elongated profiles (arrows). E3 Combined image. Asterisk indicates the same 
unstained cell body of a sensory neuron. (F) An example of a GAD65 positive neuron cell body. (G1-G3) The GAD65 immu-
nopositive elongated process (G1, green) are not double labelled with the neuronal marker NF160 (G2 red) indicating that 
they are not axons. G3 combined image. Arrows and arrowheads indicate the same element is each figure. H, High magnifica-
tion shows that the GAD65 immunopositive elongated elements (arrow) are often associated with nuclei (arrowhead). Double 
labelling for P75 (I1-I3) and Sch2e (J1-J3), a Schwann cell marker, show some GAD65 immunolabeled profiles are double 
labelled with these markers identifying the elongated profiles as non-myelinating (P75 positive) or myelinating (Sch2e positive) 
Schwann cells. Arrows and arrowheads indicate the same elements in each figure. Scale bars: A = 1 mm; B, C = 20 m; D = 1 
mm; E, F = 40 μm; G, H = 10 μm; I = 20 μm; J = 5 μm.
Molecular Pain 2009, 5:42 http://www.molecularpain.com/content/5/1/42equal which suggests that a large number of myelinated
and non-myelinated were associated with GAD65 immu-
nopositive Schwann cells.
Immunohistochemistry for common markers of immune
response showed that there was an increase in resident
(ED2 positive) and circulating macrophages (ED1 posi-
tive) in addition to an infiltration of lymphocytes (TCR
positive). The same amount of and types of immune cells
were also seen in both AdGFP and AdLacZ injected
trigeminal ganglia. The rats showed no systemic immune
response.
GAD65 expression in the trigeminal ganglion produces 
analgesia in the orofacial formalin test
The pain behavior induced by injection of formalin into
the upper lip is characterized by two phases of intense
pain behavior separated by an interphase of reduced pain
behavior (Figure 2) [14]. The pain behavior consisted of
face-rubbing (sustained face strokes of small amplitude)
directed to the upper lip and whisker pad with the ipsilat-
eral forepaw, often accompanied by the contralateral fore-
paw. Usually, the first phase is short-lasting (first 4 min of
the test), while the second phase lasts for about 30 min
starting 12 min after the beginning of the test.
When the formalin test was administered six days after the
injection of AdGAD65 in the trigeminal ganglion, there
was a significant decrease in the time spent face-rubbing
during the second phase of the formalin test (from 12 to
36 min) when compared to naïve rats that received only a
formalin injection (Figure 2). The injection of either con-
trol viruses (AdGFP or AdLacZ) did not affect any of the
formalin phases and the pain behavior was comparable to
that of naïve rats (Figure 2). The effect of injecting
AdGAD65 into the trigeminal ganglion on the formalin
test could not exclude the possibility that the effect was
due to a loss of facial sensation rather than analgesia. We
therefore carried out von Frey hair testing in adenovirus-
injected rats (Figure 3) because in models of neuropathic
pain, von Frey hair testing reveals allodynia caused by
mechanical stimulation. We would predict that if loss of
facial sensation occurred after adenovirus injection, there
would be increase of the threshold to mechanical stimula-
tion with von Frey hairs. Six days after injection of either
AdGAD65 or AdGFP, three different hairs of increased
stiffness were applied to the vibrissal pad of the rats. For
each hair, there were no changes in the response of the rats
to mechanical stimulation (Figure 3), confirming that the
effect of AdGAD65 in the formalin test was an analgesic
effect.
GABAA and GABAB receptors are expressed in sensory 
neurons of the trigeminal ganglion
In view of the previous results, we sought to determine if
AdGAD65 produced its antinociceptive effect locally in
the trigeminal ganglion through the activation of GABA
receptors. We first confirmed that GABAA and GABAB
receptors were expressed in sensory neurons of the trigem-
inal ganglion (Figure 4). GABAA receptor expression
appeared as light cytoplasmic immunostaining with
stronger intensity at the surface of the cell bodies of the
sensory neurons (Figure 4A and 4C). The expression of
GABAB receptors was only found in the cytoplasm of sen-
sory neurons (Figure 4B and 4C). Both GABAA and GABAB
receptors were seen in all types of sensory neurons.
GAD65-mediated analgesia is reversed by injection of 
bicuculline, a GABAA receptor antagonist
The finding that adenovirus-mediated expression of
GAD65 occurred principally in SGCs together with the
presence of GABA receptor in the cell bodies of sensory
neurons suggested that GABA might produce its antinoci-
ceptive effect inside the trigeminal ganglion in a paracrine
manner. To test this possibility, we injected rats with
AdGAD65, and 6 days later made a second injection into
the trigeminal ganglion with either saline, bicuculline (a
GABAA receptor antagonist) or CGP46381 (a GABAB
receptor antagonist) followed 10 minutes later by the oro-
facial formalin test. When bicuculline (200 pmol in 2 μl)
was injected into the trigeminal ganglion, GAD65-pro-
duced analgesia was reversed in the formalin test (Figure
5). The pain behavior observed from 12 to 28 min post-
injection of formalin was higher after injection of bicucul-
line when compared to injection of saline (Figure 5A). On
Adenovirus-mediated expression of GAD65 in the trigeminal gangli n produces analgesia in the formalin testFigure 2
Adenovirus-mediated expression of GAD65 in the 
trigeminal ganglion produces analgesia in the forma-
lin test. Orofacial formalin tests were performed six days 
after the injection of AdGAD65 or one of the control viruses 
(AdGFP or AdLacZ) and compared to Naïve rats. After injec-
tion of AdGAD65, there is a significant reduction of the noci-
ceptive response (RM ANOVA: F = 3.8; P < 0.001) in the 
second phase of the orofacial formalin test. AdGAD65 vs. 
Naïve: **P < 0.01, ***P < 0.001; AdGAD65 vs AdGFP: *P < 
0.05, **P < 0.01, ***P < 0.001; AdGAD65 vs AdLacZ: ##P < 
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Molecular Pain 2009, 5:42 http://www.molecularpain.com/content/5/1/42the contrary, the injection of CGP46381 (10 nmol in 2 μl)
into the trigeminal ganglion had no effect on GAD65-
mediated analgesia in the orofacial formalin test (Figure
5A). The reversion of GAD65-mediated analgesia by bicu-
culline was maximal as shown by the total pain behavior
in the second phase of the formalin test (Figure 5B). In
rats receiving AdGAD65 and bicuculline, the total pain
behavior in the second phase of the formalin test (from 12
to 44 min) was similar to that from rats injected with
either AdGFP or AdLacZ control adenoviruses (Figure 5B).
Bicuculline alone in normal rats had no effect on the for-
malin test and the pain behavior in the second phase of
the test was identical to that of control animals (Figure
5B).
Discussion
The present study shows that adenoviral transfer of the
GAD65 gene into satellite glial cells (SGCs) of the trigem-
inal ganglion is sufficient to reduce acute pain behavior
resulting from the orofacial formalin test. The application
of GAD viral vectors has previously been used to produce
analgesia but these studies differ from the present study in
two key aspects. Firstly, in the current study the adenoviral
transfer occurs principally in SGCs rather than neurons
and secondly, the antinociceptive effect is mediated at the
level of the ganglion via GABAA receptors.
Viral Targeting
The adenoviral vector used here was not specifically
designed to target glial cells, but following trigeminal gan-
glion injection many SGCs expressed GAD65 while very
few transfected neurons were seen. Other studies using
adenoviral injection into the central nervous system have
reported a similar result [15,16] while others have
reported transfection limited to neurons [17] or to both
neurons and glia [18]. It has been pointed out that factors
affecting adenoviral target-cell specificity has not been
fully explored and that some viruses have a 'natural' pref-
erence for a specific cell type [10-12]. Part of the cell spe-
cificity in our study might result from the fact that direct
injection into the ganglion makes the virus available to all
cell types whereas peripheral injection specifically targets
neurons via the peripheral branches of their axons. In
addition, because the SGCs tightly envelop neurons (see
below) they might present a physical barrier preventing
access to the neurons. Whatever the explanation for the
SGC specific adenoviral uptake, the idea that glial cell
transfection alone can cause behavioural changes in
absence of neuronal transfection, opens up further possi-
bilities for virally mediated therapeutics.
The SGC and neurons
The classic notion that glial cells serve principally as sup-
port cell for neurons has changed over the last few decades
with evidence of the many roles glial cells play in main-
Mechanical sensation of the face is unchanged after adenovi-rus-mediated expressi n of GAD65 in the trigeminal ga glionFigur  3
Mechanical sensation of the face is unchanged after 
adenovirus-mediated expression of GAD65 in the 
trigeminal ganglion. Six days after the injection of 
AdGAD65 or AdGFP, the rats were tested for their 
response to von Frey hair stimulation. For each hair, there 
was no difference in von Frey score between AdGAD65 and 
AdGFP when compared pre- and post-injection on the ipsi-
lateral side (RM ANOVA: 2 g hair, F = 0.1, P = 0.791; 10 g 
hair, F = 0.0, P = 0.926; 50 g hair, F = 0.3, P = 0.566). Simi-
larly, there was no difference between contralateral and ipsi-
lateral von Frey score pre- and post-injection after either 
injection of AdGAD65 (RM ANOVA: 2 g hair, F = 2.1, P = 
0.200; 10 g hair, F = 1.0, P = 0.356; 50 g hair, F = 1.0, P = 
0.356) or AdGFP (RM ANOVA: 2 g hair, F = 2.3, P = 0.170; 
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Molecular Pain 2009, 5:42 http://www.molecularpain.com/content/5/1/42taining proper neuronal function [19-21]. In the sensory
ganglia, SGCs and the neurons they surround are so inti-
mately associated they have been described as a func-
tional unit with the SGCs playing a key role in modulating
the perineuronal environment [22,23]. This close rela-
tionship makes SGCs an obvious target for the treatment
of different pain conditions at is reasonable to suppose
that GABA produced by SGCs will have immediate access
to the neurons they envelop that are separated from the
SGCs by an extracellular space as small as 20 nm. How-
ever for these steps to occur the SGCs must have the nec-
essary components to synthesize GABA and GABA
receptors must be present on the neurons. In fact, like
astrocytes in the CNS, SGCs participate in glutamate
metabolism through the presence of glutamine synthetase
and take up glutamate through a glial-specific glutamate
transporter, GLAST [23,24]. In normal conditions, the
glutamate is converted to glutamine by glutamine syn-
thetase (Figure 1 and [22]) but with the additional pres-
ence of GAD, the SGCs have the necessary components to
produce GABA. In vitro studies confirm that astrocytes
infected with either GAD-expressing HSV or HFV retrovi-
rus are able to synthesize GABA from glutamate [25-27].
The ability of SGCs to release GABA was concluded after
exogenously administered 3H-GABA was shown to be
released in the vicinity of sensory neurons [28-30]. In this
latter case, the secretion of GABA in the perineuronal envi-
ronment was dependent on neuronal excitation and
occurred with the increase in extracellular potassium con-
centrations.
The sensory neuron and local GABAergic systems
Primary neurons in sensory ganglion are known to pos-
sess both GABAA and GABAB receptors [31-35] but there
is some question over whether neurons or glia in the gan-
glia normally produce GABA. Although there are several
reports that GAD65 and GABA are present in both neu-
rons and SGCs of sensory ganglia [4,36,37], these papers
have not been fully substantiated by other studies. For
example, in contrast to the above studies, Liu and col-
leagues [6,8,38] found GAD immunostaining of the gan-
glia was not above background but the same group did
detect low levels of GAD by real time PCR and Western
blotting and also found low level of GABA release into the
dorsal horn [6,8,38]. There is also a consensus from stud-
ies of the spinal dorsal horn that primary afferents are not
GABA or GAD immunopositive [39-41]. Our own results
showing that immunostaining for GAD65 is not above
background in control trigeminal ganglia also supports
the idea that GAD is, at best, expressed at very low levels
in the ganglia and the functional significance is unclear.
Location of action, ganglia or spinal cord?
Several previous studies have shown that introducing
GAD genes into sensory neuron is effective in reducing
pain behavior of peripheral and central origin [6-
8,25,38,42]. In these cases, the GAD containing viral vec-
tor was delivered to peripheral targets, transported to pri-
mary sensory neuronal cell bodies and the resulting
analgesia was determined to result from the release of
GABA from primary afferent into the dorsal horn of the
spinal cord. We believe that in the present study the anti-
nociceptive effect is mediated by intraganglionic proc-
esses. The principal evidence is that GAD65 expression
was present principally in SGCs and only occasionally in
neurons. Second, the reversal of the AdGAD65-mediated
antinociception by bicuculline (a potent GABAA receptor
antagonist) injected directly into the trigeminal ganglion
also points to a local, ganglionic site of action. Direct gan-
glion injection of CGP46381, a GABAB antagonist, had no
effect showing that the analgesia is mediated by GABAA
receptors.
The idea that altering GABA within sensory ganglia can
produce analgesia is relatively new, but recently Naik and
colleagues [3] showed that direct injection of a GABAA
Sensory neurons of the trigeminal ganglion express both GABAA and GABAB receptorsFigure 4
Sensory neurons of the trigeminal ganglion express both GABAA and GABAB receptors. GABAA receptor immu-
nostaining of ganglion neurons is membrane associated (A1, red, arrows) while GABAB immunostaining is cytoplasmic (A2) 
The combined image (A3) shows some neurons are double labelled for GABAA receptor and GABAB receptor (A3, arrows). 
Scale bar = 30 μmPage 6 of 11
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GAD65-mediated analgesia is reversed by the GABAA receptor antagonist bicucullineFigure 5
GAD65-mediated analgesia is reversed by the GABAA receptor antagonist bicuculline. (A) Six days after injection 
of AdGAD65 into the trigeminal ganglion, a second injection was performed with saline, bicuculline or CGP46381 (a GABAB 
receptor antagonist), and the orofacial formalin test was carried out 10 minutes later. Bicuculline, but not CGP46381 reversed 
the AdGAD65-mediated analgesia in the second phase of the formalin test (RM ANOVA: F = 2.7; P < 0.001). AdGAD65 + 
bicuculline vs AdGAD65 + saline: **P < 0.01, ***P < 0.001. (B) Comparison of the averaged pain behavior in the second phase 
of the formalin test shows a significant difference between groups (one-way ANOVA: F = 15.6; P < 0.001). AdGAD65 pro-
duced a significany decrease in pain behavior. Bicuculline reverses AdGAD65-mediated analgesia. Bicuculline alone does not 
affect pain behavior. AdGAD65 or AdGAD65 + saline vs. AdGFP: ***P < 0.001; AdGAD65 or AdGAD65 + saline vs AdGFP: 
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Molecular Pain 2009, 5:42 http://www.molecularpain.com/content/5/1/42receptor agonists into the DRG was antinociceptive in a
model of peripheral nerve injury. The antinociceptive
effect of the GABAA receptor agonists was blocked by the
intraganglionic injection of the competitive GABAA recep-
tor antagonist, bicuculline. Naik et al [3] also showed that
muscimol given at the time of injury resulted in a long
lasting reduction of neuropathic pain while muscimol
given after the development of neuropathic pain only
resulted in a short-lived reduction in pain. Our results
confirm this latter finding of Naik and colleagues showing
that GABA or GABA agonists applied directly to the gan-
glion can produce analgesia, not only for nerve injury
induced neuropathic pain but also for inflammatory pain.
Mechanism of antinociceptive action
The most straightforward explanation for the AdGAD65-
mediated analgesia is that GABA released by SGCs inhib-
its tonic and/or induced neuronal firing of nearby neu-
rons and thus reduces nociceptive activity. However, the
most profound antinociceptive effect is in the second
phase of the formalin test and if the AdGAD65 effect was
to reduce all neuronal activity one would expect to also
see an effect in the first phase. The second phase of the for-
malin test is believed to represent tissue damage-induced
spinal sensitization, resulting in facilitated pain process-
ing [2]. Activation of nociceptive primary neurons by sub-
cutaneous injection of formalin leads to central release of
excitatory neurotransmitters or neuromediators such as
glutamate, substance P and ATP responsible for the induc-
tion and maintenance of central sensitization [1,43]. In
addition to the central release of neurotransmitters, it has
been shown that glutamate, substance P and ATP can be
released inside sensory ganglia following activation of pri-
mary sensory neurons [44-50]. Many of these released
substances are excitatory, for example, it has been sug-
gested that substance P could act in a paracrine manner in
sensory ganglia to activate neurokinin-1 receptors on
nociceptive neurons [51]. Because the effect of GABA on
primary sensory neurons is generally depolarising it is not
yet clear how an analgesic effect would be achieved. Naik
and colleagues have suggested that the GABA mediated
depolarization might clamp the membrane at the reversal
potential of Cl- and thus inactivate voltage sensitive chan-
nels such Na+ and Ca2+ [3]. An alternative proposal offered
by Naik and colleagues, that the GABA-activated Cl- cur-
rents inhibit the excitatory effects of ATP[3], is supported
by our findings that the strongest analgesic effect is on the
second, ATP related, phase of the formalin test. Whatever
the mechanism, it is clear that in our experimental condi-
tions the effect of GABA in the ganglion preferentially tar-
gets nociceptive neurons, because the effect is analgesic
rather than anaesthetic. It might be that the continued
presence of GABA in the ganglion dampens, rather than
completely abolishes neuronal activity and reduces ongo-
ing activity resulting from nerve damage that eventually
leads to peripheral or central sensitization.
Conclusion
The use of non-pharmacological approaches to treat dis-
ease, including pain, is only just beginning to be explored.
Such approaches hold great promise in their target specif-
icity both in terms of the molecules and cell types. The
current study shows the efficacy of such an approach in an
animal model and also highlights the important role that
SGCs, traditionally regarded as support cells, might play
in a therapeutic strategy.
Methods
Sub- heading for this section
4.1 Animals
Adult male Sprague-Dawley rats (Charles River) weighing
between 300 and 350 g were housed on a 12 h light/dark
cycle and given food and water ad libitum. Procedures fol-
lowed the NIH Guidelines for the Care and Use of Labo-
ratory Animals and were approved by the University of
California, San Francisco and Cedars-Sinai Medical
Center Institutional Animal Care and Use Committee.
4.2 Cannula guide implantation
Rats were anesthetized with a mixture of ketamine (75
mg/kg) and medetomidine (0.5 mg/kg) injected intraperi-
toneally. The head was placed in a stereotaxic frame, and
a 2 cm-long midline incision was made in the skin. Using
stereotaxic guidance, a burr hole (approximately 2 mm in
diameter) was drilled above the location of the maxillary
division of the left trigeminal ganglion at 6.5 mm anterior
to interaural 0 and 2.3 mm from the midline. A guide can-
nula was then anchored onto the skull using three stain-
less steel screws and dental cement. At least 5 days were
allowed for recovery from surgery before injection into
the trigeminal ganglion.
4.3 Adenoviral vectors
We used a recombinant adenovirus encoding the human
65 kDa isoform of GAD (GAD65) under the transcrip-
tional control of chicken actin ubiquitous promoter
(AdGAD65) as generated previously [52]. Two recom-
binant adenovirus, expressing either green fluorescent
protein (AdGFP) or β-galactosidase (AdLacZ) under the
control of cytomegalovirus (CMV) promoter were used as
controls. AdGFP and AdLacZ were produced at Gene Ther-
apeutics Research Institute. The backbone of all three
viruses was adenoviruses type 5 with deletions in E1 and
E3. All adenoviruses were grown and purified as previ-
ously described ([53]). Rats were injected into the left
trigeminal ganglion (see below) with 5 × 107 pfu of aden-
ovector.
4.4 Drugs
The selective GABAA receptor antagonist, (-) bicuculline
methiodide http://www.sigmaaldrich.com, and the selec-
tive GABAB receptor antagonist, CGP46381 (3-amino-
propyl-(cyclohexylmethyl)-phosphonic acid; http://Page 8 of 11
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NaCl) at a concentration of 100 μM (50 μg/ml) and 5 mM
(1.2 mg/ml), respectively. A volume of 2 μl was adminis-
tered into the trigeminal ganglion of awake animals (as
described below) corresponding to 200 pmol (100 ng) of
bicuculline or 10 nmol (2.4 μg) of CGP46381.
4.5 Trigeminal ganglion inoculation
Injections into the trigeminal ganglion were done with
the rats either under gas anesthesia or awake. For injection
of adenovirus, rats were lightly anesthetized with an inha-
lant anesthetic, delivered through a face mask (1–2% iso-
flurane-40% oxygen). For injection of GABA receptor
antagonists, awake rats were gently restrained in a trans-
parent, cone-shaped plastic bag with a tube attached to
the tip of the cone delivering oxygen at a rate of 4 L/min.
The cone had an opening so that the guide cannula was
accessible. In all cases, a 33-gauge beveled stainless steel
internal cannula was inserted into the guide cannula
(positioned over the left trigeminal ganglion as described
above) to 10.5 mm below the cortical surface. The internal
cannula was connected to a 25 μl syringe driven by a
microinjection pump set to deliver 2 μl over a 1 min
period. Rats were maintained with food and water ad libi-
tum for 6 days after injection of adenovirus.
4.6 Orofacial formalin test
We followed a protocol modified from Clavelou et al.
[14]. One day prior to the formalin test, the rats were accli-
mated for 1 h to the testing chambers (44 × 24 × 24 cm).
On the testing day, 50 μl of 2.5% formalin solution in
saline was injected subcutaneously with a 30-gauge hypo-
dermic needle into the left upper lip (side of intragangli-
onic injection of virus), lateral to the midline. The spread
of the formalin solution has been previously described
[54]. The animal was then immediately placed into the
testing chamber and continuously observed for 44 min,
during which time the nociceptive behavior (i.e. face-
rubs) was quantified. Data were collected using a compu-
ter program that automatically records the pain behavior
in successive 4 min bins. One hour after formalin injec-
tion the rats were euthanized and perfused for histological
examination of the trigeminal ganglia.
4.7 Mechanical (von Frey hair) stimulation
Rats were tested for response to von Frey hair application
as described previously [55]. Briefly, three von Frey hairs
of increasing stiffness, 2, 10 and 50 g, were applied five
consecutive times on different areas of the vibrissal pad
and in the perioral and perinasal territory. The behavioral
response of the rats was scored according to Vos et al.
(1994). For each hair, the highest score was recorded and
the results for each hair are presented separately.
4.8 Statistics
All data are expressed as mean ± SEM and were analyzed
using SigmaStat software (Systat Software, San Jose, CA).
In the formalin test, differences between groups over time
were analyzed using a mixed repeated-measure (RM)
analysis of variance (ANOVA) with Time as the repetition
factor. When significant, the RM ANOVA was followed by
multiple comparisons between groups using Bonferroni's
post hoc tests. For the analysis of the 2nd phase of the for-
malin test, a one-way ANOVA was performed to assess the
difference among groups, followed by Bonferroni's post
hoc tests for multiple comparisons between groups.
Results were considered statistically significant at P < 0.05.
For von Frey hair testing, differences between the two ade-
novirus groups (EGFP and GAD65) and changes over
time were analyzed for each hair by mixed RM ANOVA,
followed by Bonferroni's post hoc comparisons between
groups. In each group, differences between ipsilateral and
contralateral sides to the injection were tested over time
with a two-way RM ANOVA.
4.8 Perfusion and fixation
The rat was euthanized by deep anesthesia with an intra-
peritoneal injection of pentobarbital (100 mg/kg) fol-
lowed by perfusion transcardially with Tyrode's solution
followed by 10% formalin. The left and right trigeminal
ganglia were postfixed in the same fixative for 30 min, and
then transferred in a solution of 30% sucrose in PBS, pH
7.4 for 48 hours.
4.9 Tissue processing and immunohistochemistry
After cryoprotection in sucrose, the left and right trigemi-
nal ganglia were frozen and embedded together in OCT
compound. The right trigeminal ganglion was used as
internal control for protein expression. The block contain-
ing both ganglia was cut at a thickness of 10 μm on a cry-
ostat. The sections were collected on slides. For Nissl
staining section were stained for 5 minutes in 2% Cresyl
Violet then dehydrated and coverslipped using standard
protocols. For immunohistochemistry, on-slide sections
were blocked for 1 hour in 5% normal goat serum (NGS)
and 0.3% Triton X-100 in PBS, pH 7.4, and then incu-
bated overnight in the primary antiserum: GAD65
(1:1,000), glutamine synthetase (1:5,000; AbCam), P75
(1:1000, Chemicon), Schwann2E (1:1000 Developmen-
tal Studies Hybridoma Bank, Baltimore), GLAST
(1:16,000; Millipore), neurofilament 160 (NF160)
(1:200; Sigma), GABAA receptor (1:500; Chemicon) and
GABAB receptor ((1:10,000, Dr. Margeta-Mitrovic[56]) in
5% NGS and 0.3% Triton X-100. For immunofluores-
cence, a FITC- or Cy3-conjugated secondary antibody
(Jackson ImmunoResearch), diluted 1:400 in 5% NGS
and 0.3% Triton/PBS, was used for 1 h. For amplification,
a biotinylated secondary antibody, diluted 1:400 in 5%Page 9 of 11
(page number not for citation purposes)
Molecular Pain 2009, 5:42 http://www.molecularpain.com/content/5/1/42NGS and 0.3% Triton/PBS, was used for 1 hour, then the
sections were washed and incubated for 1 hour in a 1:400
ABC Elite solution diluted in 0.3% Triton/PBS. Amplifica-
tion was performed by placing sections in biotinylated
tyramide for 5 min, followed by incubation for 1 hour in
FITC-streptavidin solution, diluted 1:400 in PBS. Sections
were then washed and coverslipped with Vectashield.
Omitting the primary antibody controlled for non-spe-
cific labeling.
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